Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models

BACKGROUND: Recently, antiprogrammed cell death protein 1 (aPD-1) and antiprogrammed death-ligand 1 (aPD-L1) monoclonal antibodies (mAbs) have been approved. Even though aPD-1 and aPD-L1 mAbs target the same PD-1/PD-L1 axis, it is still unclear whether both mAbs exert equivalent pharmacological acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurino, Taiki, Matsuda, Reiko, Terui, Ayu, Suzuki, Hiroyuki, Kokubo, Tomomi, Uehara, Tomoya, Arano, Yasushi, Hisaka, Akihiro, Hatakeyama, Hiroto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057431/
https://www.ncbi.nlm.nih.gov/pubmed/32041818
http://dx.doi.org/10.1136/jitc-2019-000400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057431/
https://www.ncbi.nlm.nih.gov/pubmed/32041818
http://dx.doi.org/10.1136/jitc-2019-000400

Ejemplares similares